Patents by Inventor Andrew Pospisilik

Andrew Pospisilik has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Obesity Small Molecules
    Publication number: 20130030007
    Abstract: The present invention relates to new therapies to treat obesity and related diseases, as well as for reducing triglyceride levels and body weight.
    Type: Application
    Filed: January 7, 2011
    Publication date: January 31, 2013
    Applicant: AKRON MOLECULES GMBH
    Inventors: Josef Penninger, Andrew Pospisilik, Shane McManus
  • Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
    Publication number: 20070207946
    Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.
    Type: Application
    Filed: May 3, 2007
    Publication date: September 6, 2007
    Inventors: Andrew Pospisilik, Hans Demuth, Konrad Glund, Matthias Hoffmann, Christopher McIntosh, Ray Pederson
  • Dipeptidyl peptidase IV inhibitors and their uses for lowering blood pressure levels
    Publication number: 20050107308
    Abstract: The present invention provides new uses of DPIV-inhibitors of the present invention, and their corresponding pharmaceutically acceptable acid addition salt forms, for lowering blood pressure levels.
    Type: Application
    Filed: October 21, 2004
    Publication date: May 19, 2005
    Inventors: Andrew Pospisilik, Hans-Ulrich Demuth, Kourad Glund, Matthias Hoffmann, Christopher McIntosh, Ray Pederson
  • Methods for improving islet signaling in diabetes mellitus and for its prevention
    Publication number: 20030119736
    Abstract: The present invention discloses methods for therapeutically treating mammals, including but not limited to humans, to increase the relative insulin producing performance of endogenous pancreatic &bgr;-cells, to cause differentiation of pancreatic epithelial cells into insulin producing &bgr;-cells, to improve muscle sensitivity to insulin and other weight control efforts by the chronic oral administration of a DP IV-inhibitor. The administration causes the active form of GLP-1 and other non-nutrient stimulated growth hormones to remain biologically active longer under physiological conditions. The extended presence of such hormones, in particular in the pancreatic tissue can also facilitate differentiation and regeneration of the &bgr;-cells already present that are in need of repair.
    Type: Application
    Filed: August 9, 2002
    Publication date: June 26, 2003
    Inventors: Hans-Ulrich Demuth, Konrad Glund, J. Andrew Pospisilik, Kerstin Kuehn-Wache